pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
KRAS · news · pharmadog
← back to KRAS
News · KRAS
170
stories
26d
STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more
stat
26d
ESMO: Tango trims headcount after impressing analysts with ‘highly synergistic’ RevMed combo
fiercebiotech
27d
#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
endpoints
27d
ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
fiercebiotech
28d
ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
fiercebiotech
29d
ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3
biospace
Oct 19, 26
STAT+: The umpires getting rich off surprise medical bills, and MLB job lock
stat
Oct 19, 26
STAT+: China moves to restrict foreign biotech acquisitions
stat
Oct 19, 26
STAT+: Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
stat
Oct 19, 26
STAT+: How the No Surprises Act’s nonprofit arbitrators are operating like ‘mini gods’ and getting rich doing it
stat
Oct 19, 26
STAT+: Does Isomorphic Labs have what it takes to revolutionize drugmaking?
stat
Oct 19, 26
Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
biospace
Oct 16, 26
STAT+: RevMed’s pancreatic cancer drug nears European approval
stat
Oct 15, 26
Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
stat
Oct 15, 26
Chutes & Ladders—Bausch + Lomb's returning CEO Saunders exits again
fiercebiotech
Oct 15, 26
STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer
stat
Oct 14, 26
Verastem makes its stand as a RevMed competitor in pancreatic cancer
endpoints
Oct 14, 26
Verastem reports ‘robust’ response rate in pancreatic cancer subgroup where Rasonque struggled
biospace
Oct 14, 26
Verastem cancer drug shows early promise in small study
biopharma dive
Oct 14, 26
Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout
fiercebiotech
Oct 12, 26
RevMed's Rasonque gets a subtype data asterisk, but analysts remain bullish
biospace
Oct 9, 26
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
biopharma dive
Oct 9, 26
New data on RevMed’s Rasonque leave potential opening for other treatments
endpoints
Sep 28, 26
Merck licenses a KRAS G12D inhibitor for $400M upfront
endpoints
Sep 28, 26
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
Sep 28, 26
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
Sep 28, 26
Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D
fiercebiotech
Sep 21, 26
Opinion: STAT+: The NIH budget should be $100 billion per year
stat
Sep 18, 26
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
biospace
Sep 18, 26
Medtronic earns FDA clearance for LigaSure use with its Hugo robotic system
fiercebiotech
← prev
page 2 of 6
next →